RATIONALE: Negative mood states are characterized by both stress hormone dysregulation and serotonergic dysfunction, reflected by altered thalamic serotonin transporter (5-HTT) levels. However, so far, no study examined the individual association between cortisol response and cerebral in vivo 5-HTT levels in patients suffering from negative mood states. OBJECTIVE: The objective of this cross-sectional study was to assess the interrelation of cortisol response, thalamic 5-HTT levels, and anxiety in healthy subjects and two previously published samples of patients with unipolar major depression (UMD) and obsessive-compulsive disorder (OCD), controlling for age, gender, 5-HTT genotype, smoking, and seasonality. METHODS: Regional 5-HTT levels and cortisol response to dexamethasone-corticotropin (Dex-CRH) challenge were assessed in consecutive samples of medication-free patients suffering from UMD (N = 10) and OCD (N = 10), and 20 healthy volunteers. The intervention used was combined Dex-CRH test and [(11)C]DASB positron emission tomography. The main outcome measures were: 5-HTT binding potential (BP(ND)) in a predefined thalamic ROI, cortisol response defined as the maximum cortisol increase in the combined Dex-CRH-test, and state of anxiety from the state-trait-anxiety inventory. RESULTS: Reduced thalamic 5-HTT BP(ND) was associated with increased cortisol response (r = -0.35, p < 0.05; in patients: r = -0.53, p < 0.01) and with increased state anxiety (r = -0.46, p < 0.01), surviving correction for age, gender, 5-HTT genotype, smoking, and seasonality (p < 0.05). The 5-HTT genotype, on the contrary, was not significantly associated with cortisol response (p = 0.19) or negative mood (p = 0.23). CONCLUSION: The association between stress hormone response, thalamic 5-HTT levels, and anxiety in patients suffering from negative mood states suggests an interaction between two major mechanisms implicated in negative mood states in humans.
RATIONALE: Negative mood states are characterized by both stress hormone dysregulation and serotonergic dysfunction, reflected by altered thalamic serotonin transporter (5-HTT) levels. However, so far, no study examined the individual association between cortisol response and cerebral in vivo 5-HTT levels in patients suffering from negative mood states. OBJECTIVE: The objective of this cross-sectional study was to assess the interrelation of cortisol response, thalamic 5-HTT levels, andanxiety in healthy subjects and two previously published samples of patients with unipolar major depression (UMD) andobsessive-compulsive disorder (OCD), controlling for age, gender, 5-HTT genotype, smoking, and seasonality. METHODS: Regional 5-HTT levels andcortisol response to dexamethasone-corticotropin (Dex-CRH) challenge were assessed in consecutive samples of medication-free patients suffering from UMD (N = 10) andOCD (N = 10), and 20 healthy volunteers. The intervention used was combined Dex-CRH test and [(11)C]DASB positron emission tomography. The main outcome measures were: 5-HTT binding potential (BP(ND)) in a predefined thalamic ROI, cortisol response defined as the maximum cortisol increase in the combined Dex-CRH-test, and state of anxiety from the state-trait-anxiety inventory. RESULTS: Reduced thalamic 5-HTT BP(ND) was associated with increased cortisol response (r = -0.35, p < 0.05; in patients: r = -0.53, p < 0.01) and with increased state anxiety (r = -0.46, p < 0.01), surviving correction for age, gender, 5-HTT genotype, smoking, and seasonality (p < 0.05). The 5-HTT genotype, on the contrary, was not significantly associated with cortisol response (p = 0.19) or negative mood (p = 0.23). CONCLUSION: The association between stress hormone response, thalamic 5-HTT levels, andanxiety in patients suffering from negative mood states suggests an interaction between two major mechanisms implicated in negative mood states in humans.
Authors: A Heinz; D W Jones; G Bissette; D Hommer; P Ragan; M Knable; S Wellek; M Linnoila; D R Weinberger Journal: Pharmacopsychiatry Date: 2002-07 Impact factor: 5.788
Authors: Werner Zitterl; Martin Aigner; Thomas Stompe; Karin Zitterl-Eglseer; Karin Gutierrez-Lobos; Brigitte Schmidl-Mohl; Thomas Wenzel; Ulrike Demal; Georg Zettinig; Kurt Hornik; Kenneth Thau Journal: Neuropsychopharmacology Date: 2006-12-27 Impact factor: 7.853
Authors: J K Staley; S Krishnan-Sarin; S Zoghbi; G Tamagnan; M Fujita; J P Seibyl; P K Maciejewski; S O'Malley; R B Innis Journal: Synapse Date: 2001-09-15 Impact factor: 2.562
Authors: Maria A Oquendo; Ramin S Hastings; Yung-Yu Huang; Norman Simpson; R Todd Ogden; Xian-Zhang Hu; David Goldman; Victoria Arango; Ronald L Van Heertum; J John Mann; Ramin V Parsey Journal: Arch Gen Psychiatry Date: 2007-02
Authors: M Jabbi; J Korf; I P Kema; C Hartman; G van der Pompe; R B Minderaa; J Ormel; J A den Boer Journal: Mol Psychiatry Date: 2007-03-06 Impact factor: 15.992
Authors: Seth J Gillihan; Hengyi Rao; Lauretta Brennan; Danny J J Wang; John A Detre; Geena Mary V Sankoorikal; Edward S Brodkin; Martha J Farah Journal: Psychiatry Res Date: 2011-07-20 Impact factor: 3.222
Authors: Kathryn L Ponder; Amy Salisbury; Bethany McGonnigal; Alyse Laliberte; Barry Lester; James F Padbury Journal: Dev Psychobiol Date: 2011-05-05 Impact factor: 3.038
Authors: Johanna M Meyer; Joseph P H McNamara; Adam M Reid; Eric A Storch; Gary R Geffken; Dana M Mason; Tanya K Murphy; Regina Bussing Journal: Child Psychiatry Hum Dev Date: 2014
Authors: A Kobiella; M Reimold; D E Ulshöfer; V N Ikonomidou; C Vollmert; S Vollstädt-Klein; M Rietschel; G Reischl; A Heinz; M N Smolka Journal: Transl Psychiatry Date: 2011-08-30 Impact factor: 6.222